Stocktoria
Revolution Medicines, Inc. RVMD
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-02-13
Revolution Medicines, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M |
| R&D expense | $987.3M | $592.2M | $423.1M | $253.1M | $186.9M |
| Operating income | -$1.2B | -$689.5M | -$487.2M | -$258.3M | -$188.0M |
| Interest expense | — | — | — | $0 | $12,000 |
| Income tax | $0 | -$753,000 | -$3.5M | -$420,000 | $0 |
| Net income | -$1.1B | -$600.1M | -$436.4M | -$248.7M | -$187.1M |
| EPS (diluted) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 |
| Operating cash flow | -$897.7M | -$557.4M | -$350.6M | -$224.4M | -$147.2M |
| Free cash flow | -$913.7M | -$567.7M | -$358.3M | -$235.2M | -$153.7M |
| Cash & equivalents | $383.7M | $543.1M | $696.1M | $161.4M | $108.5M |
| Total assets | $2.4B | $2.6B | $2.1B | $811.9M | $738.0M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M |
| Shareholders' equity | $1.6B | $2.3B | $1.8B | $685.2M | $602.6M |
Source: SEC EDGAR filings · CIK 0001628171 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.